

Protein tyrosine phosphatase 1B in metabolic diseases and drug development

In the format provided by the
authors and unedited

Supplementary table 1. Summary of PTP1B inhibitors in Clinical Trials

Compound	Company	IC ₅₀ or Ki (μM) PTP1B	Clinical Phase	Status	Indications	Trials' Registration Number
DPM-1001	DepYmed, Inc.	IC ₅₀ = 0.10	Pre-clinical	Ongoing	T2DM, obesity	Unknown
JTT-551	Tobacco	Ki = 0.22	Pre-clinical	Unknown	T2DM, obesity	Unknown
DPM-1003	DepYmed, Inc.	Ki = 2.0	Pre-clinical	Ongoing	Rett Syndrome	Unknown
			Phase I	Starting 2023-2024	Rett Syndrome	Unknown
Trodesquimine	DepYmed, Inc.	IC ₅₀ = 1.0	Phase I	Terminated	T2DM, obesity Metastatic breast cancer	ClinicalTrials.gov: NCT00606112 NCT02524951
KQ-791	Kaneq Bioscience	Unknown	Phase I	Terminated	T2DM	ClinicalTrials.gov: NCT02445911
ABBV-CLS-484 (PTPN2/PTPN1)	Abbvie	IC ₅₀ < 1.0	Phase I	Ongoing	Solid Tumours	ClinicalTrials.gov: NCT04777994
ABBV-CLS-579 (PTPN2/PTPN1)	Abbvie	Unknown	Phase I	Ongoing	Solid Tumours	ClinicalTrials.gov: NCT04417465
Ertiprotafib	Pfizer	IC ₅₀ > 20	Phase II	Terminated	T2DM	Unknown ClinicalTrials.gov: NCT02524951
TTP-814	TransTech Pharma	Unknown	Phase II	Terminated	T2DM	ClinicalTrials.gov: NCT02524951
IONIS 113715	IONIS Pharmaceuticals	IC ₅₀ < 0.01	Phase II	Terminated	T2DM	ClinicalTrials.gov: NCT00365781 NCT00330330 NCT00330200 NCT00327626
IONIS PTP1BRx	IONIS Pharmaceuticals	Unknown	Phase II	Ongoing	T2DM	ClinicalTrials.gov NCT01918865